Day: September 28, 2020

Basel, 28. September 2020Basilea Pharmaceutica AG (SIX: BSLN) gab heute den Beginn der Phase-1/2-Studie FIDES-03 mit dem FGFR-Inhibitor Derazantinib bekannt. Die Multikohorten-Studie erprobt Derazantinib bei Patienten mit fortgeschrittenem Magenkrebs, deren Tumore Veränderungen (Aberrationen) im FGFR-Gen aufweisen. Derazantinib soll sowohl als Mono- als auch als Kombinationstherapie, beispielsweise mit Roches PD-L1-Checkpoint-Inhibitor Atezolizumab, untersucht werden. Basilea übernimmt als Sponsor die Leitung der Studie, während Roche Atezolizumab für die Studie zur Verfügung stellen wird.Dr. Marc Engelhardt, Basileas Chief Medical Officer, sagte: „Unsere Entwicklungsstrategie für Derazantinib ist darauf ausgerichtet, die klinische Evidenz für die Differenzierung gegenüber anderen FGFR-Inhibitoren zu stärken. Das einzigartige Kinasen-Inhibitionsprofil...

BONDUELLEA French SCA (Partnership Limited by Shares) with a capital of 56 942 095 EurosHead Office: La Woestyne 59173 Renescure, FranceRegistered under number: 447 250 044 (Dunkerque Commercial and Companies Register)2019-2020 Annual Results(July 1, 2019 – June 30, 2020)Increasing revenue and resilient profitabilityin an exceptional contextAnnual revenue growth in line with initial objectivesProfitability below target due to the health crisisCovid-19: contrasting situations and consequences depending on technologies and distribution channelsSolid balance sheet structure and financial ratiosThe controlling family shareholder, the directors and the management of the company united in the Covid-19 crisisOn September 25, 2020, the Supervisory Board, under the chairmanship of Martin Ducroquet, reviewed the statutory and consolidated...

Collaboration marks first contractual partnership with supplier of universal donor materialAmsterdam, The Netherlands, September 28, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases and Gulf Coast Regional Blood Center (GCRBC), a primary supplier of blood components to more than 170 hospitals and health care facilities, today announce a collaboration under which GCRBC will supply universal donor starting material for the manufacture of Kiadis’ off-the-shelf K-NK Natural Killer (NK) cell therapies in the United States.Kiadis’ proprietary off-the-shelf K-NK cell platform is based on NK cells from unique universal donors. This...

Pixium Vision notified of threshold crossing following passive dilutionParis, 28 September 2020 – 7:00 am CET– Pixium Vision (Euronext Growth Paris – FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, has been informed by Bpifrance Investissement of a passive crossing of the threshold of 5% of the share capital, following the increase in the total number of shares and voting rights of the Company due to the conversion by L1 Capital of an amount of convertible debt into shares.Bpifrance has not sold any shares and continues to support Pixium Vision and its strategy, through its active and continuing presence on its Board of Directors as well as through its holding of 6,150,344 shares since July 2020.Bpifrance Investissement...

BONDUELLESociété en Commandite par Actions au capital de 56 942 095 eurosSiège social : “La Woestyne” 59173 – RenescureRCS Dunkerque 447 250 044Résultats annuels 2019-2020(1er juillet 2019 – 30 juin 2020)Un chiffre d’affaires en croissance et des résultats préservésdans un contexte exceptionnelCroissance du chiffre d’affaires annuel en ligne avec les objectifs initiauxRentabilité inférieure à l’objectif liée à la crise sanitaireCovid-19 : des situations et conséquences contrastées selon les technologies et canaux de distributionStructure de bilan et des ratios financiers solidesL’actionnaire familial, les administrateurs et les dirigeants solidaires dans la crise Covid-19Le Conseil de Surveillance, réuni le 25 septembre 2020 sous la présidence de Martin Ducroquet, a examiné les comptes sociaux et consolidés...

Pixium Vision notifié d’un franchissement de seuil suite à une dilution passiveParis, 28 septembre 2020 – 7 :00 am . Pixium Vision (Euronext Growth Paris – FR0011950641), société de bioélectronique qui développe des systèmes de vision bioniques innovants pour permettre aux patients ayant perdu la vue de vivre de façon plus autonome, a été informée par Bpifrance Investissement d’un franchissement passif du seuil de 5% du capital, suite à l’augmentation du nombre total d’actions et de droits de vote de la société due à la conversion par L1 Capital d’un montant de dette convertible en actions.Bpifrance n’a vendu aucune action et continue de soutenir Pixium Vision et sa stratégie, par sa présence active, y compris au sein de son conseil d’administration, ainsi que par la détention de 6 150 344...

Exploratory efficacy data showed 88% of infants treated with Evrysdi were alive and did not require permanent ventilation at two years59% of infants were able to sit without support for at least 5 secondsNo new safety signals were identifiedIn August, the FDA approved Evrysdi for the treatment of SMA in adults and children 2 months and olderBasel, 28 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi™ (risdiplam) in infants aged 2-7 months with symptomatic Type 1 spinal muscular atrophy (SMA). The 2-year results in infants treated with the therapeutic dose of Evrysdi (17/21) showed that they continued to improve and achieve motor milestones.SUNFISH (NCT02908685) – SUNFISH is a two part, double-blind, placebo controlled pivotal study in people aged...

Schlieren/Switzerland, 28 September 2020The news release can be downloaded from the following link:AttachmentCovenant_Facilities_Sept2020

The public offering of AS LHV Group subordinated bonds ended on Friday, 25 September. As the initial issue volume of EUR 25 million was oversubscribed, LHV Group used its right to increase the issue volume to the maximum permitted volume of EUR 35 million.Altogether 3,069 investors participated in the issue, subscribing to subordinated bonds for a total of EUR 85.3 million. This means that the initial issue volume was oversubscribed 3.4 times. The subscription period started at 10.00 on 16 September and ended at 16.00 on 25 September.The Supervisory Board of AS LHV Group decided to allocate the subordinated bonds based on the following principles:All subscription orders of the same subscriber were summed up;All subscriptions up to the threshold of EUR 5,000 were fulfilled;LHV’s previous investors, whose subscriptions exceeded the threshold,...

Reedel, 25. septembril, lõppes AS-i LHV Group allutatud võlakirjade avalik pakkumine. Kuna emissiooni esialgne maht 25 miljonit eurot märgiti üle, kasutas LHV õigust suurendada emissiooni mahtu maksimaalses lubatud ulatuses 35 miljoni euroni.Märkimisest võttis kokku osa 3069 investorit, kes märkisid allutatud võlakirju kokku 85,3 miljoni euro eest. Emissiooni esialgne maht märgiti seega üle 3,4-kordselt. Märkimisperiood algas 16. septembril kell 10.00 ja lõppes 25. septembril kell 16.00.Allutatud võlakirjade jaotamisel otsustas AS-i LHV Group nõukogu jaotada võlakirjad järgmiste põhimõtete järgi:Kõik sama märkija poolt tehtud märkimiskorraldused summeeriti;Kuni 5000 euro suurused märkimised rahuldati täies mahus;LHV varasematele investoritele jaotati 38,50% nende märgitud mahust, mis on suurem kui 5000 eurot;LHV varasematele klientidele...